FDA Orange Book
Is there a generic for Docivyx?
Docivyx contains docetaxel. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
No. The Orange Book lists no active FDA-approved generic (ANDA) for Docivyx (docetaxel). The Orange Book shows its last listed patent expires March 14, 2036.
Run it in Rivvi
Map Docivyx and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Docivyx products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| solution, intravenous | 160MG/16ML (10MG/ML) | Marketed (Rx) | None | 0 | None |
| solution, intravenous | 20MG/2ML (10MG/ML) | Marketed (Rx) | None | 0 | None |
| solution, intravenous | 80MG/8ML (10MG/ML) | Marketed (Rx) | None | 0 | None |
NDA 215813, held by AVYXA HOLDINGS LLC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Docivyx patents
| Patent | Expires | Covers | Use code | NDA |
|---|---|---|---|---|
| 10398785 | March 14, 2036 | Drug product | None | 215813 |
Docivyx NDC codes
Questions
Is there a generic for Docivyx?
No. The Orange Book lists no active FDA-approved generic (ANDA) for Docivyx (docetaxel). The Orange Book shows its last listed patent expires March 14, 2036.
What is the generic name for Docivyx?
The active ingredient in Docivyx is docetaxel, per the FDA Orange Book.
When does the Docivyx patent expire?
The last patent listed for Docivyx in the Orange Book expires March 14, 2036. A listed patent expiry date is not a generic launch date.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.